These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 33237032)

  • 1. Locally advanced head and neck squamous cell carcinoma and melanoma simultaneously treated with pembrolizumab: an unusual situation.
    Mora-Fernández V; Boada A; Manzano JL; Jaka A; Ferrándiz C
    Eur J Dermatol; 2020 Dec; 30(6):743-744. PubMed ID: 33237032
    [No Abstract]   [Full Text] [Related]  

  • 2. [Regression of cutaneous basal cell and squamous cell carcinoma under pembrolizumab].
    Delaitre L; Martins-Héricher J; Truchot E; Denis D; Prophette B; Maillard H; Bénéton-Benhard N
    Ann Dermatol Venereol; 2020 Apr; 147(4):279-284. PubMed ID: 31879092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Unusual Case of Synchronous Metastatic Melanomas With Differing Response to Pembrolizumab.
    Doolan BJ; McLean C; Mar V; Moore M
    J Oncol Pract; 2019 Mar; 15(3):159-160. PubMed ID: 30861362
    [No Abstract]   [Full Text] [Related]  

  • 4. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
    Cohen EEW; Soulières D; Le Tourneau C; Dinis J; Licitra L; Ahn MJ; Soria A; Machiels JP; Mach N; Mehra R; Burtness B; Zhang P; Cheng J; Swaby RF; Harrington KJ;
    Lancet; 2019 Jan; 393(10167):156-167. PubMed ID: 30509740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.
    Saada-Bouzid E; Peyrade F; Guigay J
    Curr Opin Oncol; 2019 May; 31(3):146-151. PubMed ID: 30893146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
    Burtness B; Harrington KJ; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Basté N; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesía R; Ngamphaiboon N; Rordorf T; Wan Ishak WZ; Hong RL; González Mendoza R; Roy A; Zhang Y; Gumuscu B; Cheng JD; Jin F; Rischin D;
    Lancet; 2019 Nov; 394(10212):1915-1928. PubMed ID: 31679945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exceptional Response to PD-1 Blockade as First-Line Therapy in Head and Neck Squamous Cell Carcinoma.
    Kumai T; Komatsuda H; Minami Y; Harabuchi Y
    ORL J Otorhinolaryngol Relat Spec; 2020; 82(6):343-350. PubMed ID: 32882699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.
    Ferrarotto R; William WN; Tseng JE; Marur S; Shin DM; Murphy B; Cohen EEW; Thomas CY; Willey R; Cosaert J; Harun N; Jack Lee J; Wistuba IW; Haddad RI; Glisson BS
    Oral Oncol; 2018 Jul; 82():83-90. PubMed ID: 29909907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coincident Metastatic Melanoma and Merkel Cell Carcinoma with Complete Remission on Treatment with Pembrolizumab.
    Thiem A; Kneitz H; Schummer P; Herz S; Schrama D; Houben R; Goebeler M; Schilling B; Gesierich A
    Acta Derm Venereol; 2017 Nov; 97(10):1252-1254. PubMed ID: 28761962
    [No Abstract]   [Full Text] [Related]  

  • 10. Pembrolizumab for the treatment of head and neck squamous cell cancer.
    Ho WJ; Mehra R
    Expert Opin Biol Ther; 2019 Sep; 19(9):879-885. PubMed ID: 31317798
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01).
    Lee YG; Kang EJ; Keam B; Choi JH; Kim JS; Park KU; Lee KE; Kwon JH; Lee KW; Kim MK; Ahn HK; Shin SH; Kim HR; Kim SB; Yun HJ
    BMC Cancer; 2020 Aug; 20(1):813. PubMed ID: 32854649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab vs the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
    Lang Y; Dong D; Wu B
    Clin Drug Investig; 2020 Dec; 40(12):1137-1146. PubMed ID: 33095408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Upper Lip Squamous Cell Carcinoma the Role of Wedge Excision.
    Obradovic B
    J Craniofac Surg; 2020 Jun; 31(4):e332-e333. PubMed ID: 32068722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
    Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ
    Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412.
    Machiels JP; Tao Y; Burtness B; Tahara M; Licitra L; Rischin D; Waldron J; Simon C; Gregoire V; Harrington K; Alves GV; Figueiredo Lima IP; Pointreau Y; M Hughes BG; Aksoy S; Hetnal M; Ge JY; Brown H; Cheng J; Bidadi B; Siu LL
    Future Oncol; 2020 Jun; 16(18):1235-1243. PubMed ID: 32490686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy.
    Haque S; Yellu M; Randhawa J; Hashemi-Sadraei N
    Drug Des Devel Ther; 2017; 11():2537-2549. PubMed ID: 28919706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Inhibitor Therapy in a Liver Transplant Recipient With Melanoma.
    Schvartsman G; Perez K; Sood G; Katkhuda R; Tawbi H
    Ann Intern Med; 2017 Sep; 167(5):361-362. PubMed ID: 28761949
    [No Abstract]   [Full Text] [Related]  

  • 18. Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population.
    Chen WC; Chu PY; Lee YT; Lu WB; Liu CY; Chang PM; Yang MH
    Medicine (Baltimore); 2017 Dec; 96(52):e9519. PubMed ID: 29384959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal Growth Factor Receptor Blockade in Head and Neck Cancer: What Remains?
    Jelinek MJ; Vokes EE
    J Clin Oncol; 2019 Nov; 37(31):2807-2814. PubMed ID: 31483688
    [No Abstract]   [Full Text] [Related]  

  • 20. Prognostic value of lymph node ratio in head and neck squamous cell carcinoma.
    Talmi YP; Takes RP; Alon EE; Nixon IJ; López F; de Bree R; Rodrigo JP; Shaha AR; Halmos GB; Rinaldo A; Ferlito A
    Head Neck; 2018 May; 40(5):1082-1090. PubMed ID: 29394461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.